Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 7/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.60 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.60 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26757820 | 0.91 | NT5E (0.58) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL26757313 | 0.91 | NT5E (0.58) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL24679777 | 0.88 | RNASEL (0.57) | RNASELNT5EP2RY1 | |
| SCHEMBL22080502 | 0.88 | RNASEL (0.57) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL20692152 | 0.86 | RNASEL (0.57) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL21127931 | 0.86 | RNASEL (0.70) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL21127986 | 0.86 | RNASEL (0.70) | RNASELNT5EP2RY1P2RY2SRC | |
| SCHEMBL25691125 | 0.85 | RNASEL (0.56) | RNASELP2RY1P2RY2SRCP2RX1 | |
| SCHEMBL27111725 | 0.84 | RNASEL (0.62) | RNASELNT5EP2RY1 | |
| SCHEMBL26757806 | 0.83 | ADORA1 (0.65) | RNASELNT5EP2RY1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744845-B2 | Compounds,compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744845-B2 | Compounds,compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | RNASEL 1374/4885NT5E 382/4885P2RY1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.